The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

For US adult cancer survivors with a new alcohol use disorder diagnosis, the 1-year cumulative incidence of treatment initiation was 14.3%.

Nontraumatic subarachnoid hemorrhage remains one of the most common cardiovascular and neurological causes of death and disabilities in the world.

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders.